(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 2 November 2006 (02.11.2006)

T (10) International Publication Number WO 2006/114680 A3

(51) International Patent Classification: *C12N 1/20* (2006.01)

(21) International Application Number:

PCT/IB2006/000978

(22) International Filing Date: 21 April 2006 (21.04.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

505/MUM/2005 25 April 2005 (25.04.2005) IN

(71) Applicants and

(72) Inventors: KHAMAR, Bakulesh, Mafatlal [IN/IN]; Cadila Pharmaceuticals Ltd., Cadila Corporate Campus, Sarkhej-Dholka Road, Bhat, Ahmedabad 382 210, Gujarat (IN). MODI, INdravadn, Ambalal Cadila Pharmaceuticals Ltd. [IN/IN]; Cadila Corporate Campus, Sarkhej-Dholka Road, Bhat, Ahmedabad 382 210, Gujarat (IN). MODI, Rajiv, Indravadan [IN/IN]; Cadila Pharmaceuticals Ltd., Cadila Corporate Campus, Sarkhej-Dholka Road, Bhat, Ahmedabad 382 210, Gujarat (IN). GHOSH, Prasanta, Kumar [IN/IN]; Cadila Pharmaceuticals Ltd., Cadila Corporate Campus, Sarkhej-Dholka Road, Bhat, Ahmedabad 382 210, Gujarat (IN). DESAI, Nirav [IN/IN]; Cadila Pharmaceuticals Ltd., Cadila Corporate Campus, Sarkhej-Dholka Road, Bhat, Ahmedabad 382 210, Gujarat (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

with international search report

(88) Date of publication of the international search report: 23 August 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VACCINE ADJUVANTS

(57) Abstract: The invention relates. to a novel adjuvant *Mycobacterium w* and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. *Mycobacterium w* and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of *Mycobacterium w* and antigen containing composition, e.g. immune naêve or preimmunised status.

